摘要
To compare the respective effectiveness and safety of 600 μ g and 800 μ g of intravaginal misoprostol for complete abortion in cases of early pregnancy failure (occurring in the first 12 weeks). Method: A total of 114 women with a diagnosis of early pregnancy failure made by transvaginal ultrasonography at Rajavithi Hospital between November 25, 2002 and July 31, 2003, were assigned randomly to 2 groups of equal size. In one group the women received 600 μ g of misoprostol and in the other 800 μ g of misoprostol intravaginally. Results: The rate of complete abortion within 24 h was significantly higher in the group that received 800 μ g of misoprostol (68.4% ) than in the other group (45.6% ) (P < 0.05). There were no significant differences between the 2 groups regarding time interval between misoprostol insertion and complete abortion or side effects. Conclusion: Intravaginal misoprostol 800 μ g is significantly more effective than vaginal misoprostol 600 μ g for the termination of an early pregnancy failure, with no significant differences in side effects.
Objective： To compare the respective effectiveness and safety of 600 μg and 800 μg of intravaginal misoprostol for complete abortion in cases of early pregnancy failure （occurring in the first 12 weeks）. Method： A total of 114 women with a diagnosis of early pregnancy failure made by transvaginal ultrasonography at Rajavithi Hospital between November 25, 2002 and July 31, 2003, were assigned randomly to 2 groups of equal size. In one group the women received 600 μg of misoprostol and in the other 800 μg of misoprostol intravaginally. Results： The rate of complete abortion within 24 h was significantly higher in the group that received 800 μg of misoprostol （68. 4% ） than in the other group （45.6%） （P 〈 0. 05）. There were no significant differences between the 2 groups regarding time interval between misoprostol insertion and complete abortion or side effects. Conclusion： Intravaginal misoprostol 800 μg is significantly more effective than vaginal misoprostol 600 μg for the termination of an early pregnancy failure, with no significant differences in side effects.
